These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12447900)

  • 21. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.
    Pashov A; MacLeod S; Saha R; Perry M; VanCott TC; Kieber-Emmons T
    Glycobiology; 2005 Oct; 15(10):994-1001. PubMed ID: 15917430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies.
    Birtalan S; Zhang Y; Fellouse FA; Shao L; Schaefer G; Sidhu SS
    J Mol Biol; 2008 Apr; 377(5):1518-28. PubMed ID: 18336836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-hairpin peptidomimetics: design, structures and biological activities.
    Robinson JA
    Acc Chem Res; 2008 Oct; 41(10):1278-88. PubMed ID: 18412373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure and dynamics of the anti-AMCV scFv(F8): effects of selected mutations on the antigen combining site.
    Arcangeli C; Cantale C; Galeffi P; Rosato V
    J Struct Biol; 2008 Oct; 164(1):119-33. PubMed ID: 18662789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment.
    Magdelaine-Beuzelin C; Kaas Q; Wehbi V; Ohresser M; Jefferis R; Lefranc MP; Watier H
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):210-25. PubMed ID: 17624800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variations in antigen-antibody association kinetics as a function of pH and salt concentration: a QSAR and molecular modeling study.
    Dejaegere A; Choulier L; Lafont V; De Genst E; Altschuh D
    Biochemistry; 2005 Nov; 44(44):14409-18. PubMed ID: 16262241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering.
    Ewert S; Honegger A; Plückthun A
    Methods; 2004 Oct; 34(2):184-99. PubMed ID: 15312672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
    Masuda K; Kubota T; Kaneko E; Iida S; Wakitani M; Kobayashi-Natsume Y; Kubota A; Shitara K; Nakamura K
    Mol Immunol; 2007 May; 44(12):3122-31. PubMed ID: 17379311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The chemistry of the antibody molecule.
    Schultz PG; Yin J; Lerner RA
    Angew Chem Int Ed Engl; 2002 Dec; 41(23):4427-37. PubMed ID: 12458503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectroscopic characterization of antibodies adsorbed to aluminium adjuvants: correlation with antibody vaccine immunogenicity.
    Capelle MA; Brügger P; Arvinte T
    Vaccine; 2005 Feb; 23(14):1686-94. PubMed ID: 15705473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QSAR of multiple mutated antibodies.
    Mandrika I; Prusis P; Yahorava S; Tars K; Wikberg JE
    J Mol Recognit; 2007; 20(2):97-102. PubMed ID: 17421049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response.
    Fliri AF; Loging WT; Thadeio PF; Volkmann RA
    J Med Chem; 2005 Nov; 48(22):6918-25. PubMed ID: 16250650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel designed single domain antibody on 3-D structure of ricin A chain remarkably blocked ricin-induced cytotoxicity.
    Shuntao W; Jiannan F; Jianwei G; Leiming G; Yan L; Yingxun S; Weisong Q; Meiru H; Gencheng H; Beifen S
    Mol Immunol; 2006 Apr; 43(11):1912-9. PubMed ID: 16343623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Principles of pharmacodynamics and their applications in veterinary pharmacology.
    Lees P; Cunningham FM; Elliott J
    J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design.
    Feng J; Li Y; Zhang W; Shen B
    Immunol Lett; 2005 May; 98(2):311-6. PubMed ID: 15860233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnitude of the hydrophobic effect at central versus peripheral sites in protein-protein interfaces.
    Li Y; Huang Y; Swaminathan CP; Smith-Gill SJ; Mariuzza RA
    Structure; 2005 Feb; 13(2):297-307. PubMed ID: 15698573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.